A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
NCT04563026
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
307
Enrollment
INDUSTRY
Sponsor class
Conditions
Alcoholic Hepatitis
Interventions
DRUG:
DUR-928 30 mg
DRUG:
DUR-928 90 mg
DRUG:
Placebo+ Standard of Care (SOC)
Sponsor
Durect
Collaborators
[object Object]